Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
- PMID: 17295174
- DOI: 10.1055/s-2006-960168
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C
Abstract
Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. The severity of disease varies widely from mild illness to cirrhosis and hepatocellular carcinoma. The progression of liver fibrosis in HCV patients determines the prognosis and, thus, the need for and urgency of therapy. In addition to viral and environmental behavioral factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes of patients chronically infected with HCV. The sequencing of the human genome together with the development of high-throughput technologies has provided opportunities to distinguish discrete subsets of HCV disease and predict the disease outcome or the response to therapy. This article reviews genetic, genomic, and proteomic aspects associated with the natural history of HCV infection (i.e., viral clearance, fibrosis progression) and the response to therapy.
Similar articles
-
Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients.J Hepatol. 2008 May;48(5):708-13. doi: 10.1016/j.jhep.2008.02.010. Epub 2008 Feb 29. J Hepatol. 2008. PMID: 18329749
-
The natural history of hepatitis C virus infection.Saudi Med J. 2003 Jul;24 Suppl 2:S67-70. Saudi Med J. 2003. PMID: 12897903 Review.
-
Management of chronic hepatitis C.Minerva Gastroenterol Dietol. 2007 Mar;53(1):9-23. Minerva Gastroenterol Dietol. 2007. PMID: 17415342 Review.
-
Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.J Med Virol. 2009 Apr;81(4):610-8. doi: 10.1002/jmv.21396. J Med Virol. 2009. PMID: 19235842
-
Prevention of hepatocellular carcinoma complicating chronic hepatitis C.J Gastroenterol Hepatol. 2009 Apr;24(4):531-6. doi: 10.1111/j.1440-1746.2009.05814.x. J Gastroenterol Hepatol. 2009. PMID: 19368633 Review.
Cited by
-
Evolving challenges in hepatic fibrosis.Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36. doi: 10.1038/nrgastro.2010.97. Epub 2010 Jun 29. Nat Rev Gastroenterol Hepatol. 2010. PMID: 20585339 Review.
-
Analysis of gene expression profiles of liver stellate cells during liver regeneration in rats.Mol Cells. 2011 Jan;31(1):17-23. doi: 10.1007/s10059-011-0003-0. Epub 2010 Nov 26. Mol Cells. 2011. PMID: 21191813 Free PMC article.
-
Chemokines in the immunopathogenesis of hepatitis C infection.Hepatology. 2009 Feb;49(2):676-88. doi: 10.1002/hep.22763. Hepatology. 2009. PMID: 19177577 Free PMC article. Review.
-
Role of host genetic factors in the outcome of hepatitis C virus infection.Viruses. 2009 Sep;1(2):104-125. doi: 10.3390/v1020104. Epub 2009 Aug 5. Viruses. 2009. PMID: 21994541 Free PMC article.
-
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.Liver Int. 2012 Apr;32(4):665-74. doi: 10.1111/j.1478-3231.2011.02686.x. Epub 2011 Nov 22. Liver Int. 2012. PMID: 22103814 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources